Literature DB >> 31965154

Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey.

Tatjana S Potpara1,2, Charles Ferro3, Gregory Y H Lip4, George A Dan5, Radoslaw Lenarczyk6, Francesca Mallamaci7, Alberto Ortiz8, Pantelis Sarafidis9, Robert Ekart10, Nikolaos Dagres11.   

Abstract

The European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) jointly conducted a physician-based survey to gain insight into the management of atrial fibrillation (AF) in patients with chronic kidney disease (CKD) and adherence to current European Society of Cardiology AF Guidelines in contemporary clinical practice. Physician-based survey conducted during an 8-week period using an internet-based questionnaire sent to all EHRA and ERA/EDTA members, with voluntary and anonymous responses. Among 306 physicians (160 EHRA and 146 ERA/EDTA members; 56 countries), a multidisciplinary team for management of AF-CKD patients was available to only 20/300 respondents (6.7%) and 132/295 (44.7%) routinely screened CKD patients for AF. Oral anticoagulation (OAC) use was based on individual stroke risk in mild/moderate CKD but on shared decision-making in advanced CKD. The CHA2DS2-VASc score-based decisions were more common among cardiologists, with substantial intra- and inter-specialty heterogeneity in the use and dosing of specific OAC drugs across CKD stages, heterogeneous strategies for OAC monitoring (especially among nephrologists) and a modest impact of CKD on rate and rhythm control treatment decisions. The HAS-BLED score was generally not a determinant of OAC prescribing. Our survey provided important insights into contemporary management of AF patients with CKD in clinical practice, revealing certain differences between nephrologists and cardiologists and highlighting shared and specific knowledge gaps and unmet needs. These findings emphasize the need for streamlining the care for AF patients across different specialties and may inform development of tailored education interventions. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Chronic kidney disease; Dialysis; European Heart Rhythm Association survey; European Renal Association/European Dialysis and Transplantation Association; Oral anticoagulant therapy

Mesh:

Substances:

Year:  2020        PMID: 31965154     DOI: 10.1093/europace/euz358

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

Review 1.  Left Atrial Appendage Closure: An Alternative to Anticoagulation for Stroke Prevention in Patients with Kidney Disease.

Authors:  Srikanth Vallurupalli; Tanya Sharma; Subhi Al'Aref; Subodh R Devabhaktuni; Gaurav Dhar
Journal:  Kidney360       Date:  2021-12-08

2.  Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Tae-Min Rhee; So-Ryoung Lee; Eue-Keun Choi; Seil Oh; Gregory Y H Lip
Journal:  Front Cardiovasc Med       Date:  2022-06-10

3.  Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease.

Authors:  Gorav Batra; Angelo Modica; Henrik Renlund; Anders Larsson; Christina Christersson; Claes Held
Journal:  Open Heart       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.